UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2051-11
Program Prior Authorization/Medical Necessity
Medication Duopa™ (carbidopa/levodopa)
P&T Approval Date 7/2015, 9/2016, 9/2017, 9/2018, 9/2019, 9/2020, 9/2021, 9/2022,
8/2023, 8/2024
Effective Date 11/1/2024
1. Background:
Duopa (carbidopa/levodopa) enteral suspension is indicated for the treatment of motor
fluctuations in patients with advanced Parkinson’s disease. Duopa should be administered
continuously via an infusion pump over 16 hours through a procedurally-placed tube. Duopa
may be administered through a naso-jejunal (NJ) tube for a short period of time until a
gastrostomy tube can be placed.
2. Coverage Criteria a:
A. Initial Authorization
1. Duopa will be approved based on all of the following criteria:
a. Diagnosis of advanced Parkinson’s Disease
-AND-
b. Patient experiences a wearing “off” phenomenon that cannot be managed by
increasing the dose of oral levodopa
-AND-
c. Has undergone or has planned placement of a procedurally placed tube
Authorization will be issued for 12 months.
B. Reauthorization
1. Duopa will be approved based on the following criterion:
a. Documentation of positive clinical response to Duopa therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
©2024 UnitedHealthcare Services Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Duopa [package insert]. North Chicago, IL: AbbVie, Inc.; March 2022.
2. Sara Varanese, Zoe Birnbaum, Roger Rossi, and Alessandro Di Rocco, “Treatment of Advanced
Parkinson's Disease,” Parkinson’s Disease, vol. 2010, Article ID 480260, 9 pages, 2010.
doi:10.4061/2010/480260.
3. International Parkinson and Movement Disorder Society Evidence-Based Medicine Review:
Update on Treatments for the Motor Symptoms of Parkinson’s Disease. Movement Disorders.
2018.
Program Prior Authorization/Medical Necessity - Duopa
Change Control
Date Change
7/2015 New program.
8/2016 Administrative change to fix typo
9/2016 Annual Review. Updated references.
9/2017 Annual Review. Updated background and references.
9/2018 Annual Review. Updated references.
9/2019 Annual review. Updated references.
9/2020 Annual review. Updated references.
9/2021 Annual review. No changes.
9/2022 Annual review. Updated references.
8/2023 Annual review. No changes.
8/2024 Annual review. No changes.
©2024 UnitedHealthcare Services Inc.
2